A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Open to people ages 18-70

• Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.
• Must self-identify as either Black or African American in race in the open label addenda.
• Have severe or very severe AA, as determined by all of the following:
  • Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT Alopecia Areata Investigator Global Assessment (AA-IGA) of 3 or 4) at screening and baseline.
  • No spontaneous improvement over the past 6 months.
  • Current episode of severe or very severe AA of less than 8 years.
• Male or nonpregnant, nonbreastfeeding female participants.

• Primarily "diffuse" type of AA.
• Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.
• Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).